Stock Track | Boston Scientific Soars 6.32% in Pre-Market on Q2 Earnings Beat
Stock Track
Jul 29
Boston Scientific's stock surged 6.32% in pre-market trading after the company reported second-quarter results that exceeded analyst expectations.
The medical device maker posted adjusted earnings per share of $0.86, beating the consensus estimate of $0.83. Revenue came in at $5.442 billion, also above the expected $5.361 billion, driven by strong cardiovascular performance and emerging market growth.
The company also provided its full-year outlook, including organic revenue growth of 5-6% and adjusted EPS guidance, though the EPS forecast was slightly below some estimates. The earnings beat, coupled with positive analyst coverage and a recently announced restructuring plan, buoyed investor sentiment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.